KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses: 2009-2024

Historic Accumulated Expenses for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $128.9 million.

  • Halozyme Therapeutics' Accumulated Expenses rose 15.31% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year increase of 15.31%. This contributed to the annual value of $128.9 million for FY2024, which is 27.98% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Accumulated Expenses stood at $128.9 million for FY2024, which was up 27.98% from $100.7 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Accumulated Expenses peaked at $128.9 million during FY2024, and registered a low of $20.5 million during FY2020.
  • Over the past 3 years, Halozyme Therapeutics' median Accumulated Expenses value was $100.7 million (recorded in 2023), while the average stood at $109.8 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Accumulated Expenses slumped by 63.19% in 2020 and then spiked by 308.17% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Accumulated Expenses (Yearly) stood at $20.5 million in 2020, then grew by 19.32% to $24.4 million in 2021, then spiked by 308.17% to $99.8 million in 2022, then increased by 0.92% to $100.7 million in 2023, then climbed by 27.98% to $128.9 million in 2024.